Johnson & Johnson JNJ

Risks

Catalysts

JNJ is a high quality healthcare conglomerate with durable competitive advantages, but it faces a challenging 2026 as Stelara biosimilar erosion bites and talc litigation remains unresolved. The stock trades at 22.6x NTM P/E, which looks cheap versus its own history, but EV/EBITDA and EV/EBIT sit at 22-23% premiums to their 2y averages. The apparent P/E discount is largely an artefact of depressed trailing earnings from litigation charges, not fundamental undervaluation.

The bull case rests on Innovative Medicine growth drivers (Darzalex, Tremfya, Rybrevant, Carvykti), MedTech margin recovery (electrophysiology, orthopedics, Abiomed, surgical robotics) and ~$20b+ annual free cash flow for M&A. However, DCF fair value of ~$145-$194 sits well below the current $253 price, suggesting the market is already pricing in pipeline success and litigation resolution. The consensus target of $286.53 implies ~13% upside but is multiple based rather than cash flow based.

We rate JNJ Hold with a price target of $260, based on 21x FY+2 EPS of $12.36, implying ~3% upside. We set the target on FY+2 earnings rather than NTM EPS because the 2026 Stelara trough distorts near term estimates, and we apply a multiple below the current 22.6x NTM P/E to reflect litigation and erosion risk. The risk/reward is balanced: the talc overhang and Stelara decline are well known, but premium EV multiples and heavy insider selling limit upside. A talc resolution or positive pipeline readouts could catalyse a re-rating, but we would wait for a better entry point or clearer 2026 trough guidance.